Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nkarta (NKTX)
NASDAQ:NKTX
Nkarta (NKTX) Stock Price & Analysis
501 Followers
NKTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.28 - $16.24
Previous Close$6.58
Volume874.92K
Average Volume (3M)1.02M
Market Cap
$452.40M
Enterprise Value$303.83M
Total Cash (Recent Filing)$248.19M
Total Debt (Recent Filing)$88.34M
Price to Earnings (P/E)-2.8
Beta1.37
Next Earnings
Aug 08, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.35
Shares Outstanding70,467,620
10 Day Avg. Volume988,768
30 Day Avg. Volume1,023,758
Standard Deviation0.36
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.61
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.29
Forecast
1Y Price Target
$19.20Price Target Upside199.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Nkarta News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe expected dosing of the first patient with NKX019 for refractory lupus nephritis marks a significant milestone in the company's clinical development pipeline.
Financial StabilityNkarta has a solid financial position with $450 million in cash, which should sufficiently fund operations.
Strategic FocusThe strategic pivot towards allogeneic cell therapies for autoimmune diseases is seen positively and reflects increased investor enthusiasm.
Bears Say
Clinical Trial UncertaintyClosing of the three previously announced expansion cohorts for NKX019 due to lackluster responses.
Drug DevelopmentDeprioritization of NKX101 in AML due to lower than expected response rates in clinical trials.
Stock PerformanceThe price target for the stock has been adjusted to $15 from $16, implying a slight decrease in expected future stock performance.
---
Ownership Overview
62.18% Insiders
11.61% Mutual Funds
11.88% Other Institutional Investors
14.33% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.28 and its highest was $16.24 in the past 12 months.
What is Nkarta’s market cap?
Currently, no data Available
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Aug 08, 2024 which is in 86 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on May 09, 2024. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.545 by -$0.035.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -$0.45.
How many shares outstanding does Nkarta have?
Nkarta has 70,467,620 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.545. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Nkarta?
Among the largest hedge funds holding Nkarta’s share is RA Capital Management. It holds Nkarta’s shares valued at 52M.
---
Nkarta Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.20 (199.07% Upside)
$19.20 (199.07% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.54%
12-Months-Change
Fundamentals
Return on Equity
-28.33%
Trailing 12-Months
Asset Growth
25.92%
Trailing 12-Months
Company Description
Nkarta
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
---
NKTX Stock 12 Month Forecast
Average Price Target
$19.20
▲(199.07% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering NKTX
1 Year
1 Year Success Rate
8/16 ratings generated profit
1 Year Average Return
+37.91%
reiterated a buy rating 5 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +37.91% per trade.
---